POEMs

Patient-Oriented Evidence That Matters

Risk of GI Bleeding Highest with Rivaroxaban, Lower with Apixaban, and Lowest with PPI Cotherapy

 

Am Fam Physician. 2019 May 15;99(10):online.

Clinical Question

Which oral anticoagulants have the highest risk of causing upper gastrointestinal (GI) tract bleeding, and does cotherapy with a proton pump inhibitor (PPI) lower that risk?

Bottom Line

Among patients using oral anticoagulants alone, the risk of hospitalization for upper GI tract bleeding is highest with rivaroxaban (Xarelto) and lowest with apixaban (Eliquis). Cotherapy with a PPI reduces the risk among patients using any oral anticoagulant. (Level of Evidence = 2b)

Synopsis

The risk of serious upper GI tract bleeding associated with individual anticoagulant drug choice (with or without PPI cotherapy) is uncertain. These investigators analyzed the U.S. Medicare beneficiary files of patients 30 years or older who initiated oral anticoagulation treatment with apixaban, dabigatran (Pradaxa), rivaroxaban, or warfarin (Coumadin). The primary outcome of interest was hospitalization for upper GI tract bleeding that is potentially preventable by PPI cotherapy, including esophagitis, peptic ulcer disease, and gastritis. Multiple analyses occurred to control for covariates, including cardiovascular disease, low-dose aspirin prophylaxis, frailty, alcohol abuse, liver disease, history of previous upper GI tract bleeding, current use of other medications that affect bleeding risk (e.g., nonsteroidal anti-inflammatory drugs), and age and other demographic factors.

A total of 1,643,123 patients had 1,713,183 new episodes of oral anticoagulant treatment from January 1, 2011, through September 30, 2015. The mean age of the patients was 76.4 years and the indication for anticoagulation was atrial fibrillation for 74.9% of them. In patients receiving anticoagulant treatment without PPI cotherapy, the adjusted incidence of hospitalization for upper GI tract bleeding was significantly higher in those who received rivaroxaban compared with those who received dabigatran, warfarin, or apixaban (144 per 10,000 person-years vs. 120, 113, and 73, respectively). For patients receiving

POEMs (patient-oriented evidence that matters) are provided by EssentialEvidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see https://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

This series is coordinated by Sumi Sexton, MD, Editor-in-Chief.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.

 

 

Want to use this article elsewhere? Get Permissions

CME Quiz

More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Dec 1, 2019

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article